+

WO2001066689A3 - Nouveaux acides nucleiques et polypeptides - Google Patents

Nouveaux acides nucleiques et polypeptides Download PDF

Info

Publication number
WO2001066689A3
WO2001066689A3 PCT/US2001/004942 US0104942W WO0166689A3 WO 2001066689 A3 WO2001066689 A3 WO 2001066689A3 US 0104942 W US0104942 W US 0104942W WO 0166689 A3 WO0166689 A3 WO 0166689A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
polypeptides
novel nucleic
novel
present
Prior art date
Application number
PCT/US2001/004942
Other languages
English (en)
Other versions
WO2001066689A2 (fr
Inventor
Y Tom Tang
Chenghua Liu
Vinod Asundi
Chongjun Xu
Tom Wehrman
Feiyan Ren
Yunqing Ma
Ping Zhou
Qing A Zhao
Yonghong Yang
Radoje T Drmanac
Jie Zhang
Rui-Hong Chen
Aidong J Xue
Jian-Rui Wang
Original Assignee
Hyseq Inc
Y Tom Tang
Chenghua Liu
Vinod Asundi
Chongjun Xu
Tom Wehrman
Feiyan Ren
Yunqing Ma
Ping Zhou
Qing A Zhao
Yonghong Yang
Radoje T Drmanac
Jie Zhang
Chen Rui Hong
Aidong J Xue
Wang Jian Rui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyseq Inc, Y Tom Tang, Chenghua Liu, Vinod Asundi, Chongjun Xu, Tom Wehrman, Feiyan Ren, Yunqing Ma, Ping Zhou, Qing A Zhao, Yonghong Yang, Radoje T Drmanac, Jie Zhang, Chen Rui Hong, Aidong J Xue, Wang Jian Rui filed Critical Hyseq Inc
Priority to US10/221,278 priority Critical patent/US20040034208A1/en
Priority to AU2001245280A priority patent/AU2001245280A1/en
Priority to CA002402293A priority patent/CA2402293A1/fr
Priority to EP01918174A priority patent/EP1261743A2/fr
Publication of WO2001066689A2 publication Critical patent/WO2001066689A2/fr
Publication of WO2001066689A3 publication Critical patent/WO2001066689A3/fr
Priority to US10/291,172 priority patent/US20030228584A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention se rapporte à de nouveaux acides nucléiques, à de nouvelles séquences de polypeptides codées par ces acides nucléiques et à des utilisations de ceux-ci.
PCT/US2001/004942 2000-03-07 2001-03-05 Nouveaux acides nucleiques et polypeptides WO2001066689A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/221,278 US20040034208A1 (en) 2001-03-05 2001-03-05 Novel nucleic acids and polypeptides
AU2001245280A AU2001245280A1 (en) 2000-03-07 2001-03-05 Novel nucleic acids and polypeptides
CA002402293A CA2402293A1 (fr) 2000-03-07 2001-03-05 Nouveaux acides nucleiques et polypeptides
EP01918174A EP1261743A2 (fr) 2000-03-07 2001-03-05 Nouveaux acides nucleiques et polypeptides
US10/291,172 US20030228584A1 (en) 2000-03-07 2002-11-08 Novel nucleic acids and polypeptides

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US51970500A 2000-03-07 2000-03-07
US09/519,705 2000-03-07
US57445400A 2000-05-19 2000-05-19
US09/574,454 2000-05-19
US59619300A 2000-06-17 2000-06-17
US09/596,193 2000-06-17
US61684700A 2000-07-14 2000-07-14
US09/616,847 2000-07-14
US66536300A 2000-09-19 2000-09-19
US09/665,363 2000-09-19
US69326700A 2000-10-20 2000-10-20
US09/693,267 2000-10-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/291,172 Continuation-In-Part US20030228584A1 (en) 2000-03-07 2002-11-08 Novel nucleic acids and polypeptides

Publications (2)

Publication Number Publication Date
WO2001066689A2 WO2001066689A2 (fr) 2001-09-13
WO2001066689A3 true WO2001066689A3 (fr) 2002-05-30

Family

ID=27560092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004942 WO2001066689A2 (fr) 2000-03-07 2001-03-05 Nouveaux acides nucleiques et polypeptides

Country Status (4)

Country Link
EP (1) EP1261743A2 (fr)
AU (1) AU2001245280A1 (fr)
CA (1) CA2402293A1 (fr)
WO (1) WO2001066689A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953682B2 (en) 2000-02-10 2005-10-11 Millennium Pharmaceuticals, Inc. Nucleic acid sequences encoding adenylate kinase, phospholipid scramblase-like, DNA fragmentation factor-like, phosphatidylserine synthase-like, and atpase-like molecules and uses therefor
EP1343899A2 (fr) * 2000-12-14 2003-09-17 Bayer Aktiengesellschaft Regulation de l'uridine kinase humaine
US20040072997A1 (en) * 2000-12-20 2004-04-15 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002074906A2 (fr) * 2001-03-16 2002-09-26 Eli Lilly And Company Proteines de mammiferes lp et reactifs associes
JP2005536439A (ja) 2001-09-18 2005-12-02 ジェネンテック・インコーポレーテッド 腫瘍の診断及び治療のための組成物と方法
AU2003226444A1 (en) * 2002-04-01 2003-10-13 Asahi Kasei Pharma Corporation Vascularization controlling gene
CA2486060A1 (fr) * 2002-05-15 2003-11-27 Avalon Pharmaceuticals Gene lie au cancer servant de cible pour la chimiotherapie
DK1513934T3 (da) 2002-06-06 2011-05-02 Oncotherapy Science Inc Gener og polypeptider relateret til humane coloncancersygdomme
GB0215295D0 (en) * 2002-07-02 2002-08-14 Inpharmatica Ltd Proteins
JP2007523608A (ja) * 2003-03-26 2007-08-23 ノバルティス アクチエンゲゼルシャフト サイクリックａｍｐ応答エレメントアクティベータータンパク質およびそれに関連する使用
US7361747B2 (en) * 2003-05-22 2008-04-22 The University Of Hong Kong Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
GB0320878D0 (en) * 2003-09-05 2003-10-08 Celltech R&D Ltd A protein involved in carcinoma
CA2543789A1 (fr) 2003-10-23 2005-05-06 Illumigen Biosciences, Inc. Detection de mutations dans un gene associees a la resistance a l'infection virale, oas1
AU2004316290C1 (en) 2003-11-06 2012-02-02 Seagen Inc. Monomethylvaline compounds capable of conjugation to ligands
JP5234734B2 (ja) 2004-06-01 2013-07-10 ジェネンテック， インコーポレイテッド 抗体−薬物結合体および方法
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
WO2006097335A1 (fr) * 2005-03-18 2006-09-21 Universität Zürich Nouvel element de la voie de signalisation wg/wnt
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
WO2007030930A1 (fr) 2005-09-13 2007-03-22 National Research Council Of Canada Methodes et compositions permettant de moduler l'activite des cellules tumorales
EP2240196A2 (fr) * 2008-01-22 2010-10-20 Compugen Ltd. Nouveau peptide dérivé de clusterine
JP2013504585A (ja) 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
EA034462B1 (ru) 2009-11-24 2020-02-11 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
EA024730B1 (ru) 2010-04-15 2016-10-31 Медимьюн Лимитед Пирролбензодиазепиновые соединения, их конъюгаты, фармацевтические композиции, содержащие указанные конъюгаты, и применение указанных конъюгатов
CN107335062B (zh) 2010-06-08 2021-09-24 基因泰克公司 半胱氨酸改造的抗体和偶联物
US20120121595A1 (en) * 2010-10-11 2012-05-17 University Of Southern California FRAGMENT OF SECRETED HEAT SHOCK PROTEIN-90ALPHA (Hsp90ALPHA) AS VACCINES OR EPITOPE FOR MONOCLONAL ANTIBODY DRUGS OR TARGET FOR SMALL MOLECULE DRUGS AGAINST A RANGE OF SOLID HUMAN TUMORS
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
EP2707723B1 (fr) 2011-05-12 2016-02-10 Genentech, Inc. Procédé lc-ms/ms de surveillance de réactions multiples pour détecter des anticorps thérapeutiques dans des échantillons animaux à l'aide de peptides de signature d'infrastructure
BR112014009050B1 (pt) 2011-10-14 2022-06-21 Medimmune Limited Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas
AU2013224591A1 (en) 2012-02-22 2014-07-24 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
WO2014057120A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps - pyrrolobenzodiazépine
EP2766048B1 (fr) 2012-10-12 2014-12-10 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
CN105102068B (zh) 2012-10-12 2018-06-01 Adc疗法责任有限公司 吡咯并苯并二氮杂卓-抗体结合物
CA2887899C (fr) 2012-10-12 2020-03-31 Adc Therapeutics Sarl Conjugues anticorps anti-cd22 - pyrrolobenzodiazepine
US10736903B2 (en) 2012-10-12 2020-08-11 Medimmune Limited Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
JP6392763B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
CA2887894C (fr) 2012-10-12 2019-10-29 Adc Therapeutics Sarl Conjugues anticorps anti-psma - pyrrolobenzodiazepine
US9649390B2 (en) 2013-03-13 2017-05-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CA2901941C (fr) 2013-03-13 2020-04-07 Spirogen Sarl Pyrrolobenzodiazepines et leurs conjugues
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CA2918139A1 (fr) 2013-08-12 2015-02-19 Genentech, Inc. Conjugues anticorps-medicament dimerique 1-(chloromethyl)-2,3-dihydro-1 h-benzo [e]indole, et methodes d'utilisation et de traitement
WO2015052535A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
MX2016007578A (es) 2013-12-16 2016-10-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
RU2689388C1 (ru) 2013-12-16 2019-05-28 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
SG11201604905WA (en) 2013-12-16 2016-07-28 Genentech Inc Peptidomimetic compounds and antibody-drug conjugates thereof
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
RU2017107502A (ru) 2014-09-12 2018-10-12 Дженентек, Инк. Антитела и конъюгаты, сконструированные введением цистеина
JP6622293B2 (ja) 2014-09-12 2019-12-18 ジェネンテック， インコーポレイテッド アントラサイクリンジスルフィド中間体、抗体−薬物複合体、及び方法
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
SG11201702079UA (en) 2014-09-17 2017-04-27 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
WO2016083468A1 (fr) 2014-11-25 2016-06-02 Adc Therapeutics Sa Conjugués anticorps-pyrrolobenzodiazépine
AU2015358532C1 (en) 2014-12-03 2020-10-29 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201608197D0 (en) 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
EP3458101B1 (fr) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Conjugués anticorps-protac et procédés d'utilisation
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
WO2017214024A1 (fr) 2016-06-06 2017-12-14 Genentech, Inc. Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
JP7093767B2 (ja) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピンプロドラッグ及びその抗体コンジュゲート
EP3522933B1 (fr) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Procédés de préparation de conjugués anticorps-médicament
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
HUE054689T2 (hu) 2017-02-08 2021-09-28 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
US11260101B2 (en) * 2017-02-28 2022-03-01 Jinan University Repair peptide for use in promoting post-traumatic tissue repair and regeneration, and application thereof
WO2018192944A1 (fr) 2017-04-18 2018-10-25 Medimmune Limited Conjugués de pyrrolobenzodiazépine
KR20190141666A (ko) 2017-04-20 2019-12-24 에이디씨 테라퓨틱스 에스에이 항-axl 항체-약물 접합체로의 병용 요법
WO2018229222A1 (fr) 2017-06-14 2018-12-20 Adc Therapeutics Sa Régimes posologiques pour l'administration d'un cam anti-cd19
FR3069156B1 (fr) * 2017-07-21 2019-08-09 Universite de Bordeaux Clusterine pour son utilisation dans le traitement des micro-angiopathies thrombotiques
SI3668874T1 (sl) 2017-08-18 2022-04-29 Medimmune Limited Pirolobenzodiazepinski konjugati
KR20220156974A (ko) 2017-09-20 2022-11-28 주식회사 피에이치파마 타일란스타틴 유사체
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
CN113056287A (zh) 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 缀合的化学降解诱导剂及使用方法
WO2020123275A1 (fr) 2018-12-10 2020-06-18 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
EP4426727A2 (fr) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps
WO2024220546A2 (fr) 2023-04-17 2024-10-24 Peak Bio, Inc. Anticorps et conjugués anticorps-médicament et procédés d'utilisation, processus synthétiques et intermédiaires

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 6 February 1997 (1997-02-06), WANG ET AL.: "Direct submission", XP002908399, Database accession no. U51114 *
WATSON ET AL.: "The science used in recombinant DNA industry. Recombinant DNA; A short course", 1983, W.H. FREEMAN AND COMPANY, NEW YORK, XP002945246 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US9562049B2 (en) 2012-12-21 2017-02-07 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9567340B2 (en) 2012-12-21 2017-02-14 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations

Also Published As

Publication number Publication date
WO2001066689A2 (fr) 2001-09-13
EP1261743A2 (fr) 2002-12-04
AU2001245280A1 (en) 2001-09-17
CA2402293A1 (fr) 2001-09-13

Similar Documents

Publication Publication Date Title
WO2001075067A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057188A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001057190A3 (fr) Acides nucleiques et polypeptides
WO2002022660A3 (fr) Noveaux acides nucleiques et polypeptides
WO2001066689A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002031111A3 (fr) Acides nucleiques et polypeptides
WO2001088088A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002059260A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003054152A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003025148A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002070539A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2003023013A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2002081731A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053312A8 (fr) Nouveaux acides nucleiques et polypeptides
WO2001053455A3 (fr) Nouveaux acides nucleiques et polypeptides associes
WO2004009834A3 (fr) Nouveaux acides nucleiques et polypeptides secretes
WO2003029271A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2004080148A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001079449A3 (fr) Acides nucleiques et polypeptides nouveaux
WO2002018424A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2004087874A3 (fr) Acides nucleiques et polypeptides
WO2003080795A8 (fr) Nouveaux acides nucléiques et polypeptides sécrétés
WO2001002571A3 (fr) Nouvel antagoniste du recepteur d'interleukin-1 et ses utilisations
WO2005049806A3 (fr) Nouveaux acides nucleiques et polypeptides
WO2001075068A3 (fr) Proteines secretee et polynucleotides codant pour ces proteines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2402293

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001918174

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10291172

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001918174

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10221278

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001918174

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载